Lumida
/AGL
⌘K
agilon health inc

agilon health inc

AGL
$87.38USD-0.10%-0.09 today

MARKET CAP

1.5B

P/E (TTM)

FWD P/E

DAY RANGE

$87 – $91

52W RANGE

$7
$133

AI Summary

Stalk
Sell NowMedium

AGL remains in a Stage 3 corrective phase with price beneath declining EMAs and SMA, reinforcing a bearish medium-term context. Tight consolidation near the lower end of the 90–96 range signals lack of demand, and the active Bearish Pivot Point confirms downward mean-reversion bias. Short-term rejection of minor EMAs provides a clear sell-into-rally execution opportunity. Execution now into any minor upticks under the 50-day SMA aligns with current structure.

  • Q2 revenue grew 7% YoY to $1.5B; medical margin turned positive at $197M vs –$53M prior.
  • Adjusted EBITDA of $70M in Q2 vs a –$83M loss last year.
  • Negative profitability factor and negative earnings yield raise valuation concerns.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.5B$2.4B$4.3B$6.1B$5.9B
YoY %+57.0%+80.7%+40.4%-2.1%
P / Sales6.6x2.7x1.2x0.1x0.0x
EV / Sales6.3x2.8x1.5x0.3x0.2x
Gross Profit, Adj.$65.7M$111.4M$69.7M$4.8M$-160.0M
YoY %+69.4%-37.4%-93.1%-3405.5%
Margin %4.3%4.7%1.6%0.1%-2.7%
EV / Gross Profit144.9x60.5x89.8x383.3x-7.8x
EBITDA, Adj.$-357.6M$-91.6M$-212.0M$-264.1M$-398.6M
YoY %+74.4%-131.4%-24.6%-50.9%
Margin %-23.5%-3.8%-4.9%-4.4%-6.7%
EV / EBITDA-26.6x-73.6x-29.5x-7.0x-3.2x
EBIT$-372.2M$-105.4M$-232.1M$-292.1M$-463.2M
YoY %+71.7%-120.3%-25.8%-58.6%
Margin %-24.5%-4.4%-5.4%-4.8%-7.8%
EV / EBIT-25.6x-63.9x-27.0x-6.4x-2.7x
Net Income$-406.5M$-106.6M$-262.6M$-260.2M$-391.3M
YoY %+73.8%-146.4%+0.9%-50.4%
Net Margin-26.7%-4.5%-6.1%-4.3%-6.6%
EPS (GAAP)-$27.25-$6.50-$16.00-$15.75-$23.75
YoY %+76.1%-146.2%+1.6%-50.8%